LQ-041

N/A

Report date: 2023/02/28 13:21:43

Base Information

Drug NameLQ-041
Drug Alias NameLQ041LQ-041LQ-041（超长效IL-5纳米抗体注射液）LQ-041（异源二价纳米抗体Fc融合蛋白）
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-5 inhibitors
TargetsInterleukin-5
Therapy Area/IndicationsHypereosinophilic SyndromeEosinophilic Granulomatosis With PolyangiitisAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Novamab Biopharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Novamab Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsHypereosinophilic SyndromeEosinophilic Granulomatosis With PolyangiitisAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A